
    
      Multi-center, combination phase II study, open-label, non-comparative, non-randomized.

      All progressive or recurrent solid tumours will be included in the Phase II study, provided
      there are no curative options anymore.

      Total expected number of patients (minimum maximum): 54 to 90 (2-stage design)
    
  